Develops drug candidates for heart and metabolic conditions and neuropathic pain, and sells an approved heart-failure medicine to wholesalers.
10-K for FY2025, filed Mar 5, 2026We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our…View ↗
We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM…View ↗
We are developing pilavapadin, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We have completed…View ↗
We continue to manufacture and make INPEFA available to patients and prescribers. We maintain a small virtual contract sales force for…View ↗
We have developed LX9851, an orally-delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic…View ↗
Wholesalers and limited retail pharmacies buy INPEFA, and Lexicon earns the sale when it delivers the drug. Licensees pay upfront and at milestones, with additional royalties on sales.
10-K for FY2025, filed Mar 5, 2026 8-K, filed Aug 6, 2026In March 2026, Novo Nordisk initiated a Phase 1 study investigating single and multiple ascending doses of LX9851 compared to placebo in…View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service (Net product revenue) ↗$49.8M
10-K for FY2025, filed Mar 5, 2026
$49.8M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
|
9.4% |
Product, FY2025
$4.6M Sources
|
Sold outright |
|
License
Licensed
|
91% |
License, FY2025
$45M Sources
|
Licensed |
Lexicon sells INPEFA mainly to major and selected regional wholesalers, which resell it to retail pharmacies, hospitals, government agencies and other institutions; it also sells to limited retail pharmacies and uses a mail-order pharmacy to dispense the drug.
10-K for FY2025, filed Mar 5, 2026
No. It lost $50.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$14MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 167.1x in 4 years, from $298K in FY2021 to $49.8M in FY2025, about 260% a year.
Competes with Bristol Myers Squibb, Cytokinetics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Vertex, Novo Nordisk, Novartis, and Merck
10-K for FY2025, filed Mar 5, 2026We expect that our principal competition for sotagliflozin in the treatment of hypertrophic cardiomyopathy would include generic beta…View ↗
Loading...